News

Article

Capsugel and Pulmatrix Collaborate on Pulmonary Disease Treatments

The collaboration will allow the companies to develop and manufacture novel inhaled therapeutics.

Capsugel and Pulmatrix formed a collaboration to develop and manufacture novel inhaled therapeutics for pulmonary diseases, according to a Feb. 16, 2016 press announcement from the companies. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE -based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

iSPERSE is a dense and dispersible-engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility, and flow-rate independence. Several products leveraging the iSPERSE platform are in development, two of which are a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease, and an inhaled anti-fungal (PUR1900) for cystic fibrosis.

“This collaboration provides us with access to Capsugel’s spray dry technology, scale-up capabilities, and state-of-the-art equipment to support our growing pipeline of internal and partnered development programs,” said Robert Clarke, PhD, CEO of Pulmatrix in a press announcement.

Source: Capsugel

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content